Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

PloS one

Volumn 7, Issue 4, 2012, Pages

  Kieffer, Tara L ^a   De Meyer, Sandra ^b   Bartels, Doug J ^b   Sullivan, James C ^b   Zhang, Eileen Z ^b   Tigges, Ann ^b   Dierynck, Inge ^b   Spanks, Joan ^b   Dorrian, Jennifer ^b   Jiang, Min ^b   Adiwijaya, Bambang ^b   Ghys, Anne ^b   Beumont, Maria ^b   Kauffman, Robert S ^b   Adda, Nathalie ^b   Jacobson, Ira M ^b   Sherman, Kenneth E ^b   Zeuzem, Stefan ^b   Kwong, Ann D ^b   Picchio, Gaston ^b  

^a VERTEX PHARMACEUTICALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; MACROGOL DERIVATIVE; OLIGOPEPTIDE; RECOMBINANT PROTEIN; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG COMBINATION; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR EVOLUTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84863550914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034372     Document Type: Article

References (0)